The advancements in technology and manufacturing processes have allowed the development of new derivatives, biosimilar or advanced improved versions for approved antibodies each year for treatment regimen. There are more than 700 antibody-based molecules that are in different stages of phase I/II/ III clinical trials targeting new unique targets. To date, approximately more than 80 monoclonal antibodies (mAbs) have been approved. A total of 7 novel antibody therapeutics had been granted the first approval either in the United States or European Union in the year 2019, representing approximately 20% of the total number of approved drugs. Most of these licenced mAbs or their derivatives are either of hybridoma origin or their improvised engineered versions. Even with the recent development of high throughput mAb generation technologies, hybridoma is the most favoured method due to its indigenous nature to preserve natural cognate antibody pairing information and preserves innate functions of immune cells. The recent advent of antibody engineering technology has superseded the species level barriers and has shown success in isolation of hybridoma across phylogenetically distinct species. This has led to the isolation of monoclonal antibodies against human targets that are conserved and non-immunogenic in the rodent. In this review, we have discussed in detail about hybridoma technology, its expansion towards different animal species, the importance of antibodies isolated from different animal sources that are useful in biological applications, advantages, and limitations. This review also summarizes the challenges and recent progress associated with hybridoma development, and how it has been overcome in these years to provide new insights for the isolation of mAbs.

随着技术和制造工艺的进步，每年可以为治疗方案开发新的衍生物，生物仿制药或先进的改进版本的已批准抗体。有超过700种基于抗体的分子处于I / II / III期临床试验的不同阶段，以新的独特靶标为靶标。迄今为止，已经批准了大约80多种单克隆抗体（mAb）。在2019年，总共有7种新颖的抗体疗法在美国或欧盟获得了首批批准，约占批准药物总数的20％。这些获得许可的mAb或其衍生物大多数是杂交瘤起源的或即兴改造的版本。即使最近开发了高通量mAb产生技术，杂交瘤是最受青睐的方法，因为其固有的性质可以保留天然的同源抗体配对信息并保留免疫细胞的固有功能。抗体工程技术的最新出现已取代了物种水平的障碍，并已成功地分离出系统发育不同物种间的杂交瘤。这导致分离出抗人靶标的单克隆抗体，其在啮齿动物中是保守的且非免疫原性的。在这篇综述中，我们详细讨论了杂交瘤技术，其向不同动物物种的扩展，从不同动物来源分离的可用于生物学应用的抗体的重要性，优势和局限性。这篇综述还总结了杂交瘤发展的挑战和最新进展，